Table 2 Comparison of clinical features, treatment details, and outcomes between patients with autoimmune pancreatitis and chronic pancreatitis

Clinical features

 Age (years)

69.0 (59–73)

56.5 (20–85)

0.018^*

 Gender (male/female)

7/1

77/15

1.000

 Therapeutic purpose for ESWL

  Chronic pain (+/−)

0/8

42/50

0.019^*

  Pancreatic attack (+/−)

1/7

32/60

0.265

  Preservation of pancreatic function (+/−)

7/1

18/74

<0.001^*

Treatment details

 Location of treated pancreatic stones

  Pancreatic head

6/2

83/9

0.213

  Pancreatic body

3/5

15/77

0.153

  Pancreatic tail

0/8

1/91

1.000

 Pancreatic duct stenosis proximal to stones (+/−)

4/4

22/70

0.107

 Endoscopic treatment

6/2

66/26

1.000

  Endoscopic pancreatic sphincterotomy (+/−)

3/5

39/53

1.000

  Endoscopic pancreatolithotripsy (+/−)

3/5

45/47

0.716

  Endoscopic pancreatic stenting (+/−)

3/5

32/60

1.000

Outcomes

 Extraction of pancreatic stones in MPD (+/−)

5/3

71/21

0.394

 Shift to surgical treatment (+/−)

1/7

3/89

0.284

 Complications associated with ESWL (+/−)

0/8

8/84

1.000

 Relapse of pancreatic stones in MPD (+/−)

1/7

22/70

0.678